Tag: cancer

Antibody-drug conjugates (ADCs) require multiple assays for analytical and bioanalytical characterization due to their heterogeneous and dynamic nature. These assays can help address questions...

The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody...

Results from ongoing studies of two bispecific, hexavalent, antibodies, 1R-(E1)-(E1) and 1R-(15)-(15), for treating breast, pancreatic and other solid cancers, were presented during a...

Monoclonal Antibodies (mAbs), once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way,...

Interim results from a phase I clinical trial of brentuximab vedotin(SGN-35, Adcetris™, Seattle Genetics/Millennium: The Takeda Oncology Company) in combination with chemotherapy for the...

Data reported today demonstrating that prolonged treatment with Brentuximab Vedotin (SGN-35; Adcetris™, Seattle Genetics) beyond 16 cycles of therapy was associated with clinically meaningful...

Throwing stones at castle walls is one way to attack an enemy, but sneaking inside makes the target much more vulnerable. Researchers at Cedars-Sinai's...

Earlier this month French pharmaceutical giant Sanofi-aventis acquired an exclusive world-wide license to one of Oxford BioTherapeutics’ internal preclinical antibody programs. Sanofi-aventis intends to...

Results of a Phase II study of trastuzumab (Herceptin®, Genentech) in combination with DM1 (T-DM1), an investigational HER2 antibody-drug conjugate being developed by Genentech,...